@article{2c0f68f27a374db68329720922389377,
title = "Best Practice Management of Patients With Chronic Obstructive Pulmonary Disease: A Case-Based Review",
abstract = "Chronic obstructive pulmonary disease (COPD) is associated with a high clinical and economic burden and is the fourth leading cause of death in the United States. The management of patients with COPD aims to minimize and control symptoms, prevent exacerbations, and improve quality of life. We provide an illustrated case study of a female patient with typical progression of COPD and describe the diagnosis, assessment, and management strategy, referring to the evidence seen in recent studies that supports the treatment decisions.",
keywords = "COPD, bronchodilator, inhaled corticosteroid, symptoms",
author = "Michelle Vega-Olivo and Halpin, {David M.G.} and Han, {Mei Lan K.} and Hanania, {Nicola A.} and Ravi Kalhan and Lipson, {David A.} and Neil MacIntyre and Dawn Midwinter and Marjorie Stiegler and Corinne Young and Martinez, {Fernando J.} and Criner, {Gerard J.}",
note = "Funding Information: Funding. Ravi Kalhan reports grants from the National Institutes of Health, National Heart, Lung and Blood Institute during the conduct of the study. Fernando J. Martinez reports grant support from the National Institutes of Health. The IMPACT study was funded by GSK (study number CTT116855; NCT02164513). The funders of the study had a role in the study design, data analysis, data interpretation, and writing of the report.Disclosures. In compliance with standard ethical guidelines, the authors report the following relationships with business or industry that would pose a conflict of interest: Michelle Vega-Olivo reports speaker programs for Genentech and Boehringer Ingelheim. David M.G. Halpin reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Pfizer and Sanofi, and nonfinancial support from Boehringer Ingelheim and Novartis. MeiLan K. Han reports personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Verona, Mylan, and Merck, and research support from Novartis and Sunovion. Nicola A. Hanania was an investigator on the IMPACT study and reports receiving personal fees from GSK, AstraZeneca, Boehringer Ingelheim, Sanofi Genzyme, Novartis, Regeneron, Genentech, Sunovion, and Mylan for serving as an advisor or consultant, and also received research support from GSK, Boehringer Ingelheim, and AstraZeneca. Ravi Kalhan reports grants and personal fees from Boehringer Ingelheim, AstraZeneca, and GSK, grants from PneumRx (BTG) and Spiration, and personal fees from CVS Caremark, Aptus Health, Boston Scientific, and Boston Consulting Group. David A. Lipson, Dawn Midwinter, and Marjorie Stiegler are employees of GSK and hold stocks and shares in GSK. Corrine Young reports personal fees from Association of Pulmonary Advanced Practice Providers, American College of Chest Physicians, AstraZeneca, GlaxoSmithKline, Janssen, Griffols, and American Board of Internal Medicine. F.J. Martinez reports COPD- and respiratory disease-related non-financial support from GlaxoSmithKline, respiratory disease-related personal fees and non-financial support from AstraZeneca, COPD-related personal fees and non-financial support from GlaxoSmithKline, Boehringher Ingelheim and Sanofi/Regeneron, and COPD-related personal fees from Chiesi, CSL Behring, Novartis, Polarean, Pulmonx and Theravance/Viatris. Gerard J. Criner reports personal fees from Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Broncus Medical, Chiesi, CSA Medical, Eolo, Gala Therapeutics, GSK, Helios Medical, Medtronic, Merck, Mereo BioPharma, NGM Pharmaceuticals, Novartis, Nuvaira, Olympus, Philips Respironics, Pulmonx, Respivant Sciences, The Implementation Group, and Verona. Funding Information: Funding. Ravi Kalhan reports grants from the National Institutes of Health , National Heart, Lung and Blood Institute during the conduct of the study. Fernando J. Martinez reports grant support from the National Institutes of Health . The IMPACT study was funded by GSK (study number CTT116855; NCT02164513 ). The funders of the study had a role in the study design, data analysis, data interpretation, and writing of the report. Funding Information: Editorial support, in the form of writing assistance, including preparation of the draft manuscript under the direction and guidance of the authors, collating and incorporating authors{\textquoteright} comments for each draft, assembling the table, grammatical editing, and referencing) was provided by Alexandra Berry, PhD, and Maria Guillermina Casabona, PhD, at Fishawack Indicia Ltd, United Kingdom, part of Fishawack Health, and was funded by GSK. Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
month = jul,
day = "1",
doi = "10.1016/j.nurpra.2022.03.010",
language = "English (US)",
volume = "18",
pages = "730--735",
journal = "Journal for Nurse Practitioners",
issn = "1555-4155",
publisher = "Elsevier Inc.",
number = "7",
}